These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 25590436)

  • 41. Corneal concentrations following systemic administration of amphotericin B and its lipid preparations in a rabbit model.
    Goldblum D; Rohrer K; Frueh BE; Theurillat R; Thormann W; Zimmerli S
    Ophthalmic Res; 2004; 36(3):172-6. PubMed ID: 15103209
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effectiveness, Tolerability, and Safety of Different Amphotericin B Formulations in Invasive Fungal Infections: A Multicenter, Retrospective, Observational Study.
    Cavassin FB; Magri MMC; Vidal JE; de Moraes Costa Carlesse FA; Falci DR; Baú-Carneiro JL; Breda GL; de Araújo Motta F; de Miranda Godoy CS; de Bastos Ascenço Soares R; De Oliveira CS; Mendes AVA; Morales HP; Montes PS; Taborda M; Rego CM; Félix MA; Katopodis PP; da Silva do Ó JR; Abrão MPL; Pereira TTT; Queiroz-Telles F
    Clin Ther; 2024 Apr; 46(4):322-337. PubMed ID: 38403508
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety.
    Hamill RJ; Sobel JD; El-Sadr W; Johnson PC; Graybill JR; Javaly K; Barker DE
    Clin Infect Dis; 2010 Jul; 51(2):225-32. PubMed ID: 20536366
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety analysis of liposomal amphotericin B in adult patients: anaemia, thrombocytopenia, nephrotoxicity, hepatotoxicity and hypokalaemia.
    Shigemi A; Matsumoto K; Ikawa K; Yaji K; Shimodozono Y; Morikawa N; Takeda Y; Yamada K
    Int J Antimicrob Agents; 2011 Nov; 38(5):417-20. PubMed ID: 21885259
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Retrospective analysis of risk factors for liposomal amphotericin B-associated nephrotoxicity.
    Yokota T; Yoshikawa N; Arimori K; Ikeda R
    Pharmazie; 2020 Nov; 75(11):599-601. PubMed ID: 33239137
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Renal impairment and amphotericin B formulations in patients with invasive fungal infections.
    Saliba F; Dupont B
    Med Mycol; 2008 Mar; 46(2):97-112. PubMed ID: 18324488
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis.
    Lewis RE; Liao G; Hou J; Chamilos G; Prince RA; Kontoyiannis DP
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1253-8. PubMed ID: 17261624
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Incidence, Predictors, and Impact on Hospital Mortality of Amphotericin B Nephrotoxicity Defined Using Newer Acute Kidney Injury Diagnostic Criteria.
    Rocha PN; Kobayashi CD; de Carvalho Almeida L; de Oliveira Dos Reis C; Santos BM; Glesby MJ
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4759-69. PubMed ID: 26014956
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain.
    Aguado JM; Lumbreras C; González-Vidal D;
    Clin Microbiol Infect; 2004 Sep; 10(9):785-90. PubMed ID: 15355408
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lipid formulations of amphotericin B as first-line treatment of zygomycosis.
    Petrikkos GL
    Clin Microbiol Infect; 2009 Oct; 15 Suppl 5():87-92. PubMed ID: 19754765
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Renal effects of amphotericin B lipid complex.
    Luke RG; Boyle JA
    Am J Kidney Dis; 1998 May; 31(5):780-5. PubMed ID: 9590187
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation.
    Espada R; Valdespina S; Dea MA; Molero G; Ballesteros MP; Bolás F; Torrado JJ
    J Antimicrob Chemother; 2008 May; 61(5):1125-31. PubMed ID: 18285313
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Are there risk factors for acute renal failure in adult patients using deoxycholate amphotericin B?
    Tuon FF; Koenig F; Jacometto D; Rocha JL
    Rev Iberoam Micol; 2013 Jan; 30(1):21-4. PubMed ID: 22995903
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy, Biodistribution, and Nephrotoxicity of Experimental Amphotericin B-Deoxycholate Formulations for Pulmonary Aspergillosis.
    López-Sánchez A; Pérez-Cantero A; Torrado-Salmerón C; Martin-Vicente A; García-Herrero V; González-Nicolás MÁ; Lázaro A; Tejedor A; Torrado-Santiago S; García-Rodríguez JJ; Capilla J; Torrado S
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760126
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Amphotericin B lipid complex (ABLC)-associated hypertension: case report and review.
    Rowles DM; Fraser SL
    Clin Infect Dis; 1999 Dec; 29(6):1564-5. PubMed ID: 10585814
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B.
    Loo AS; Muhsin SA; Walsh TJ
    Expert Opin Drug Saf; 2013 Nov; 12(6):881-95. PubMed ID: 23931455
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A double-blinded, placebo-controlled, multicenter clinical trial of N-acetylcysteine for preventing amphotericin B-induced nephrotoxicity.
    Karimzadeh I; Khalili H; Sagheb MM; Farsaei S
    Expert Opin Drug Metab Toxicol; 2015; 11(9):1345-55. PubMed ID: 26050706
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluating real-life clinical and economical burden of amphotericin-B deoxycholate adverse reactions.
    Horwitz E; Shavit O; Shouval R; Hoffman A; Shapiro M; Moses AE
    Int J Clin Pharm; 2012 Aug; 34(4):611-7. PubMed ID: 22674178
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reduction of nephrotoxicity associated with amphotericin B deoxycholate.
    Johnson JR
    Clin Infect Dis; 2004 Jan; 38(2):303; author reply 306-7. PubMed ID: 14699469
    [No Abstract]   [Full Text] [Related]  

  • 60. Assessment of effective renal plasma flow, enzymuria, and cytokine release in healthy volunteers receiving a single dose of amphotericin B desoxycholate.
    Pai MP; Norenberg JP; Telepak RA; Sidney DS; Yang S
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3784-8. PubMed ID: 16127053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.